Register for our S/EIS Fund
Register

featured in

fund overview

o2h Ventures Limited has launched the first fund in the UK solely focused on early stage biotech therapeutic and related AI opportunities in the UK. The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster. The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers.

A shift in focus of the large pharmaceutical companies from developing innovation in-house to acquiring innovation externally increased demand for the best science providing earlier exit options. The fund is headquartered in the Mill SciTech Park, Cambridge, where it can provide the incubation and support as part of a community to the companies it has invested in to help them achieve a critical value inflexion point. The team at o2h have access to some of the most exciting ideas through its live grass roots working relationships fostered with entrepreneurs and scientists over many years.

For more information email us at- invest@o2h.com

Information memorandum

If you would like further details and would like to read our full Information Memorandum you can request to download it below:

Request to download

EIS fund benefits

The Enterprise Investment Scheme is a government-backed initiative designed to encourage investment into unquoted and/or AIM-listed companies. It offers generous incentives in the form of tax reliefs, to investors who are prepared to take on the risks of this kind of investment.

Income Tax Relief

Loss Relief

Capital Gains tax(CGT) Relief

CGT Reinvestment Relief

Inheritance Tax(IHT) Relief

Register your interest

S(EIS) tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

SEIS gives you £25k tax relief from HMRC

COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

the team

o2h ventures team

Sunil Shah

Chief Executive Officer

Sunil's Biography

Sunil Shah

Chief Executive Officer

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h Ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

Connect on Linkedin

Andy Morley

Principal

Andy's Biography

Andy Morley

Principal

Andy is a Medicinal Chemist with over 25 yrs working in major pharma (Sano -Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He has authored and inventor of over 55 publications and patents. He is been working full-time with o2h Ventures since 2013 to lead the scientific evaluation of the investments and also provides scientific support on key projects within the portfolio. He is the CSO of Opal Oncology and had been CSO for two o2h early-stage collaborations.

Connect on Linkedin

Cengiz Tarhan

Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most proli c and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the rst university spin-outs to oat on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three

Connect on Linkedin

passion for EIS investing

Large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing us prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas in the through its live working relationships fostered over many years working as a discovery services company giving it far earlier access than competitors to the most promising companies. Early stage companies often need more than just money, o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering company’s incubation in its the Mill SciTech Park, in Cambridge, UK, and/or the option to jump-start their research activity from o2h Discovery in Ahmedabad, India. The fund is structures to be (S)EIS compliant proving generous income, Inheritance and capital gains tax for UK tax payers.

our EIS investments

(made personally by the Fund Managers)

exonate

Exonate

Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.
sentinel

Sentinel

From initial concept to the delivery of candidate drugs – we’re a drug discovery company specialising in cutting-edge cancer treatment.
phoremost

Phoremost

PhoreMost® has developed a next-generation phenotypic screening platform called ‘SITESEEKER®’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.
talisman

Talisman

Talisman Therapeutics, a spinout from the University of Cambridge, is a stem cell research and development company committed to revolutionising the discovery of treatments for Alzheimer’s disease.
oppilotech

Oppilotech

Science-led ambitious start up focused on the development of antibacterial compounds with novel mechanisms of action against drug resistant organisms.
acacia-pharma

Acacia Pharma

Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.
iota

Iota

IOTA Pharmaceuticals has been established to bring you the tools and technologies for Fragment-based Drug Discovery(FBDD) and High-content Screening(HCS).
5-alarm-bio

5 Alarm Bio

5 Alarm Bio is a company dedicated for designing anti-ageing therapies.
small-pharma

Small Pharma

Small Pharma is forging a new path in pharmaceutical development by bridging the gap between academia and industry.
oxford-drug-design

Oxford Drug Design

Oxford Drug Design (formerly InhibOx) is a biotechnology company focused on internal drug discovery. The lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes.
arecor

Arecor

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.
repositive

Repositive

The Repositive platform enables researchers to browse through multiple repositories for the human genomic data they need to power their research.
privitar

Privitar

Privitar facilitates broader use of data while adopting an uncompromising approach to protecting confidential information.
Heart felt

Heartfelt Technologies

Heartfelt Technologies exists to help patients, their families, carers and doctors, to reduce hospital re-admission rates from congestive heart failure de-compensation.
Stemnovate

Stemnovate

Stemnovate at Cambridge, UK are developing a ‘liver on a chip’ system supported by a $1m Innovate UK award. The platform is based on cutting edge stem cell and micro engineering platform technologies at University of Edinburgh and Cambridge University.
Metrion

Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel drug discovery services.

Fund Overview

Fund Fund Overview
Min Investment £25,000, there is no maximum investment. The current EIS investment limit in any tax year is £1m.
Fund Size £1m to start investing, with an initial target of £10m
Tax Advantages If you are a UK tax payer, you maybe eligible for S/EIS tax relief on investment
Differentiation Grassroots working relationships providing early access to deals.
Diversification We will typically use your subscription to build a portfolio of 5-12 companies, which will likely be focused on therapeutic biotech and related AI opportunities
Liquidity Capital is returned to you only when we are able to sell the shares in your portfolio companies.
Expected Exit 5-8 years. We will seek to exit investments after 3 years to preserve any S/EIS reliefs. We may hold investments longer if the business case warrants this, for similar reasons we may exit businesses earlier than 3 years
Speed of Investments While we will aim to deploy capital in 12-18 months, we will only invest when we find suitably exciting opportunities, which may on occasion extend this period
Risks You should only subscribe if you able to bear losing your entire investment
Closing Dates 11 December 2018, 4 April 2019, 31 July 2019, 10 October 2019.

Investor Suitability

Which investor type best describes you?

I am a High Net-Worth Individual
  • I have an annual income of more than £100k or net assets of over £250k.
Review & confirm

I am a Sophisticated Investor
  • I have sufficient experience with early-stage investment to certify as a sophisticated investor.
Review & confirm

I am neither a High Net-Worth Individual nor a Self-Certified Sophisticated Investor.
  • I do not fit into either of the other categories.
Review & confirm

I am an Advisor
  • I represent a professional investor
 Register

NOTE:The fund is only available to investors who wish to be treated as professional investors and are suitable to be classed as professional investors.

Self certification as a high net worth individual

I declare that I am a certified high net worth individual for the purposes of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a certified high net worth individual because at least one of the following applies

  1. the property which is my primary residence or any loan secured on that residence;

  2. any rights of mine under a qualifying contract of insurance within the meaning of the Financial Services and Markets Act 2000 (Regulated Activities) Order 2001; or

  3. any benefits (in the form of pensions or otherwise) which are payable on the termination of my service or on my death or retirement and to which I am (or my dependants are), or may be, entitled.

I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Sign by clicking here Sign by clicking here

Self certification as a high net worth individual

I declare that I am a self-certified sophisticated investor for the purposes of the Financial Services and Markets Act (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a self-certified sophisticated investor because at least one of the following applies:

I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Self certification as a high net worth individual

Sorry, you are not eligible to invest in this fund

Register as an Investor

You are not eligible to register